Reappraising the Diagnostic Accuracy of Post-Treatment Whole-Body Scans for Differentiated Thyroid Carcinoma

Abstract

Initial treatment for differentiated thyroid carcinoma (DTC) often consists of surgery and the administration of radioiodine. In this context, post-treatment Whole-Body Scans (ptWBS) are currently recommended, but data on its diagnostic accuracy are rare. The aim of the study was to evaluate the performance of ptWBS for distant metastasis in DTC patients. We included DTC patients who received radioiodine and underwent ptWBS between 2009–2015. The medical data were independently reviewed by two specialists to evaluate the concordance of positive distant ptWBS uptake and distant metastasis documented by imaging exams (gold standard). We studied 268 DTC patients. The mean age was 46±16 years (82% women), and papillary thyroid carcinoma was diagnosed in 87% of the patients. The median tumor size was 2.7 cm, 40% had lymph node involvement, and 11% had distant metastasis. Twenty-eight patients (10%) had distant ptWBS uptake, and nine of them (32%) were false-positives. In addition, nine false-negative ptWBS uptakes were identified. The overall performance of ptWBS showed 68% sensitivity and 96% specificity with significantly different performance according to the American Thyroid Association (ATA) risk groups. While the ptWBS performance for ATA low-intermediate-risk showed 29% sensitivity, 97% specificity, and Kappa of 0.19, the ATA high-risk group ptWBS displayed high sensitivity (82%), specificity (100%), and good agreement (Kappa 0.74). ptWBS is useful for a subgroup of ATA high-risk DTC patients. The overall poor performance of ptWBS suggests that it should be reconsidered for routine use in ATA at low to intermediate risk: the exam has little value to this subgroup.

Key words

differentiated thyroid carcinoma - whole-body scan - radioiodine - prognosis - false-positive

Publikationsverlauf

Eingereicht: 01. April 2020

Angenommen nach Revision: 01. Juli 2020

Artikel online veröffentlicht:
04. August 2020

• References

• 1 Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424
• 2 Haugen BR, Alexander EK, Bible KC. et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016: 1-133
• 3 Ahn BC. Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics 2012; 2: 392-402
• 4 Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002; 43: 1188-1200
• 5 Pacini F, Agate L, Elisei R. et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131 I whole body scan: Comparison of patients treated with high 131 I activities versus untreated patients. J Clin Endocrinol Metab 2001; 86: 4092-4097
• 6 Fatourechi V, Hay ID, Mullan BP. et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?. Thyroid 2000; 10: 573-577
• 7 Oh JR, Byun BH, Hong SP. et al. Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹⁸F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 2011; 38: 1459-1468
• 8 Yildirim-Poyraz N, Ozdemir E, Amutkan C. et al. False-positive iodine-131 whole body scan due to a benign dermal lesion; intradermal nevus ((131)I uptake in a benign nevus). Ann Nucl Med 2013; 27: 786-790
• 9 Chaussé G, Kader T, Abikhzer G. et al. Asthmatic exacerbation as a cause of false-positive whole-body iodine scan in a patient with treated papillary thyroid carcinoma. Clin Nucl Med 2018; 43: 256-257
• 10 Ceccarelli C, Pacini F, Lippi F. et al. An unusual case of a false-positive iodine-131 whole body scan in a patient with papillary thyroid cancer. Clin Nucl Med 1988; 13: 192-193
• 11 Wang R, Zhou K, Fan Q. et al. A false-positive I-131 finding of duodenum diverticulum in thyroid cancer evaluation by SPECT/CT: A case report. Medicine (Baltimore) 2018; 97: e9997
• 12 Maciejewski A, Czepczynski R, Ruchala M. False-positive radioiodine whole-body scan due to a renal cyst. Endokrynol Po 2018; 69: 736-739
• 13 Shapiro B, Rufini V, Jarwan A. et al. Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole-body 131-I scans in patients with thyroid cancer. Semin Nucl Med 2000; 30: 115-132
• 14 Buton L, Morel O, Gault P. et al. False-positive iodine-131 whole-body scan findings in patients with differentiated thyroid carcinoma: report of 11 cases and review of the literature. Ann Endocrinol (Paris) 2013; 74: 221-230
• 15 Hannoush ZC, Palacios JD, Kuker RA. et al. False positive findings on I-131 WBS and SPECT/CT in patients with history of thyroid cancer: Case series. Case Rep Endocrinol 2013; 8568347
• 16 Agate L, Bianchi F, Brozzi F. et al. Less than 2 % of the low- and intermediate-rIsk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan. Eur Thyroid J 2019; 8: 90-95
• 17 Garger YB, Winfeld M, Friedman K. et al. In thyroidectomized thyroid cancer patients, false-positive I-131 whole body scans are often caused by inflammation rather than thyroid cancer. J Investig Med High Impact Case Rep 2016; 25: 2324709616633715
• 18 Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. Am J Nucl Med Mol Imaging 2012; 2: 362-385
• 19 Ma Chao, Kuang Anren, Xie Jiawei. et al. Possible explanations for patients with discordant findings of serum thyroglobulin and ¹³¹I whole-body scanning. J Nucl Med 2005; 46: 1473-1480
• 20 Durante C, Puxeddu E, Ferretti E. et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843
• 21 Chakravarty D, Santos E, Ryder M. et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011; 121: 4700-4711
• 22 Baudin E, Do Cao C, Cailleux AF. et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003; 88: 1107-1111
• 23 Webb RC, Howard RS, Stojadinovic A. et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: A meta-analysis involving 3947 patients. J Clin Endocrinol Metab 2012; 97: 2754-2763
• 24 Scheffel RS, Zanella AB, Dora JM. et al. Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma. Thyroid 2016; 26: 1623-1629
• 25 Rosario PW, Ward LS, Carvalho GA. et al. Thyroid nodules and differentiated thyroid cancer: Update on Brazilian consensus. Arqui Brasil. Endocrinol Metab 2013; 57: 205-232
• 26 Tuttle M, Morris LF, Haugen B et al. Thyroid-differentiated and anaplastic carcinoma (chapter 73). AJCC Cancer Staging Manual. 8th ed. Edge MB, Greene SB, Byrd F et al. (eds). New York, NY, USA: Springer International Publishing; 2017: 873–890
• 27 Nava CF, Zanella AB, Scheffel RS. et al. Impact of the updated TNM staging criteria on prediction of persistent disease in a differentiated thyroid carcinoma cohort. Arch. Endocrinol Metab 2019; 63: 5-11
• 28 Cooper DS, Dohertu GM, Haugen BR. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
• 29 Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-35
• 30 Oral A, Yazici B, Eraslan C. et al. Unexpected false-positive I-131 uptake in patients with differentiated thyroid carcinoma. Mol Imaging Radionucl Ther 2018; 9: 99-106